DDInter576 DDInter837
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Disulfiram {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) IL11
IL11 {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is downregulated by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKB2
NFKB2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is upregulated by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is downregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Golimumab
Disulfiram {u} (Compound) upregulates {v} (Gene) LAMA3
LAMA3 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may lead to a major life threatening interaction when taken with Golimumab
Disulfiram (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may lead to a major life threatening interaction when taken with Golimumab
Disulfiram (Compound) upregulates IL11 (Gene) and IL11 (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Golimumab
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is downregulated by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Disulfiram (Compound) upregulates NFKB2 (Gene) and NFKB2 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Disulfiram (Compound) upregulates DNAJB2 (Gene) and DNAJB2 (Gene) is upregulated by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Disulfiram (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is downregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Disulfiram (Compound) upregulates LAMA3 (Gene) and LAMA3 (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Golimumab